Join Our List
Symbol: MZEI Exchange: OTCBB Shares I/O: 242.20 million Est. Float: 177.41 million 52 Week Range: $0.016 - $0.42
Contact Information
Investor Relations, Market Pulse Toll Free: 800.290.8935 Email: info@market-pulse.com Latest News: MZEI News Recent Developments:
July 7, 2010 - Medizone Files for International Patent Protection Get the Full Story
June 1, 2010 - AsepticSure Eliminates Food-Borne Pathogens Get the Full Story
April 30, 2010 - MoneyTV with Donald Baillargeon, 4/30 Get the Full Story
April 27, 2010 - MRSA Eliminated in Youth Sports Equipment Get the Full Story
April 13, 2010 - Medizone International to Attend Investors Conference Get the Full Story
March 19, 2010 - MEDIZONE INTERNATIONAL INC Financials Get the Full Story
March 16, 2010 - Medizone International Announces Giant Step Forward for AsepticSure(TM) Get the Full Story
March 15, 2010 - MEDIZONE INTERNATIONAL INC Files SEC form 10-K, Annual Report Get the Full Story
March 8, 2010 - AsepticSure(TM) Eliminates All Pathogens Get the Full Story
February 4 , 2010 - AsepticSure(TM) Hospital Sterilization System Demonstrates Total Eradication of Super Bugs Get the Full Story
January 20, 2010 - Medizone International Announces Greatly Enhanced AsepticSure(TM) Patent Protection Get the Full Story
January 5, 2010 - Medizone International Successfully Completes Third Round of AsepticSure(TM) Test Program Get the Full Story
The Company
Medizone International, Inc. (OTCBB: MZEI) is a research and development company engaged in developing AsepticSure™ System, a novel ozone-based technology. AsepticSure™ is a portable decontamination and sterilization system for hospitals, government buildings, sports training facilities, schools and other critical infrastructure that might currently require, or need to be prepared for countermeasures capability from contamination by infectious biological agents. It is anticipated that AsepticSure™ will be extremely cost effective and adaptable to virtually any situation anywhere and have a global reach. A government variant is being developed for bio-terrorism counter measures.
Hospital Acquired Infections (HAIs) are one of the most common complications of hospital care. Nearly 2 million patients develop HAIs, which contribute to 99,000 deaths each year and $28 billion to $33 billion in health care costs. The most common HAI-causing bacteria is methicillin-resistant Staphylococcus aureus, or MRSA.
Medizone began mockup trials in January 2010 for both public (hospital) and government (bio-terrorism countermeasures) applications. Results obtained during early February 2010 show that every full-scale test run completed in their hospital room mockup facility has resulted in the total elimination of all bacteria present in the room.
In March 2010, Medizone successful completed the first full round of room scale testing with its AsepticSure™ sterilization system. Successful decontamination by AsepticSure™ to the 6 log standard or greater has been demonstrated with C.difficile, E coli, Pseudomonas aeruginous, MRSA, VRE and Bacillius subtilis. These results have confirmed the laboratory findings reported earlier, but what is of even greater significance are the insights gained into the technical modifications necessary to accommodate the unique requirements of decontaminating within a hospital environment.
The AsepticSure™ system is capable of decontamination to the previously unobtainable 6 log standard on all hospital surfaces, hard or soft. Medizone is now able to greatly reduce the time required to achieve 6 log kills on hard surfaces to 30 minutes of exposure. With the charge time and destruct time for reuse of the space factored in, that translates to a room turn around time of 80 minutes, a 40 minute saving in total turn around time from their original target of 2 hours. Fabric exposure requires an additional 15 minutes to achieve the same 6 log kill rate, which represents a full turn around for a thorough cleaning of about 95 minutes for all surface materials. This reduction in room turn around time from 120 minutes to 95 minutes for a thorough sterilization will be viewed very favorably by hospitals.
From a commercial viewpoint, the higher the “kill rate” in the shortest turn around time, the more favorably physicians and hospital administrators will view the system. Accordingly, Medizone now believes that the performance profile of its AsepticSure™ Sterilization System will exceed all the prerequisite requirements of affordability, practicability and unmatched efficacy, which will catapult it into the world market.
The Medizone International Research Laboratory is located in Innovation Park at Queen's University at Kingston, Ontario, Canada. This laboratory is fully equipped to meet bio-safety level 2 laboratory standards and is dedicated exclusively to Medizone research. This facility provides Medizone International a platform for laboratory research which has the potential to expand beyond AsepticSure™. Given the outstanding range of bactericidal kill rates Medizone has achieved to date with the pathogens most often associated with hospital derived infections, it has become clear there are opportunities abounding to expand scientific horizons through collaborative arrangements in many diverse and exciting new applications.
The AsepticSure™ Sterilization System
Beginning in 2008, Medizone's management repositioned the company to pursue an initiative in the field of hospital sterilization. Following laboratory results with Bacillus subtilis , an internationally recognized surrogate for Anthrax, that produced 7 log reductions (sterilization), Medizone has expanded their research and business plan to include bio-terrorism countermeasures as well as hospital sterilization and critical infrastructure decontamination. Since this technology is not considered a medical treatment or a diagnostic, its development pathway is not subject to a stringent and expensive regulatory review process.
During July 2009, the company filed a patent application for the AsepticSure™ technology in order to establish protection of its commercial rights to this technology internationally. The patent covers disinfection for rooms and their contents within all healthcare facilities, mobile or stationary, and other critical infrastructure such as schools and government buildings. A second patent application has been filed which in combination with its previous patent application for AsepticSure™ filed in 2009, affords the company greatly enhanced protection for both the hospital version of AsepticSure™ and the government variant intended for bio-terrorism countermeasures.
To meet the unique challenges of hospital acquired infections, Medizone is utilizing an expanded and enhanced design team that is experienced in bringing products from the research stage to full production. Medizone is finalizing the design of a new, fully integrated AsepticSure™ system for hospital beta testing. Medizone will build four highly instrumented prototype units for use in its hospital program, thereby enabling precise performance assessment of all AsepticSure™ systems as concurrent outcome measures, which will form the basis for final production design work, manufacturing and ultimately commercialization later this year. This design will achieve the same results as the current beta prototype while also being a major step forward and very close to what they expect the full production prototype will be.
The Markets
Biological contamination of medical treatment areas such as hospitals and chronic care facilities has recently been identified by several world renowned public health institutions, including the Centers for Disease Control, as one of the greatest threats to public health and safety in the industrial world.
Post-surgical infections significantly increase the chance of hospital readmission and death and cost as much as $60,000 per patient, according to Duke University Medical Center researchers who conducted the largest study of its kind to date. Patients with surgical site infections due to MRSA were 35 times more likely to be readmitted and seven times more likely to die within 90 days compared to uninfected surgical patients. For the seven hospitals examined the total estimated cost resulting from surgical site infections due to MRSA was more than $19 million. The cost-saving potential for community hospitals is enormous.
The United States Congress and various State Legislatures have taken official notice of the issues associated with Hospital Acquired Infections. Laws are being enacted in a majority of States to require that hospitals report the number of Hospital Acquired Infections. Medicare will no longer reimburse hospitals for treating hospital acquired infections. Demand for an effective product is huge.
Medizone assisted in the formation of the Canadian Foundation for Global Health (CFGH), a not-for-profit foundation based in Ottawa, Canada. Medizone's Board of Directors have adopted a business philosophy of "creating a corporate paradigm in which the corporation’s profit follows its social contribution." The establishment of this foundation fits into that paradigm not only by being positioned to attract the highest quality professionals possible to their research projects. It is envisioned that as Medizone's products and treatments become ready for market, the Foundation may play a vital role as a distribution source for developing countries with varying price breaks depending on the country's needs and the availability of international assistance.
Medizone International introduced Arkady Mandel MD, PhD, D.Sc as a new member to their team of esteemed consultants. Dr. Mandel was elected in 2009 to the Board of Directors of the Canadian Foundation for Global Health. "In joining our research and development team Dr. Mandel will contribute immensely to our understanding of the complex chemistry behind the broad and potent bactericidal interaction of AsepticSure™" commented DR Michael Shannon, Medizone's Director of Medical Affairs, who continued, "DR Mandel brings to Medizone almost 25 years of experience with ozone and holds over 30 international patents pertaining to ozone related medical applications. His enormous depth of knowledge and expertise in the biochemistry, physiology and immunology associated with ozone medicine will prove invaluable to our Company particularly as we attempt to both expand and fortify our Intellectual Property position internationally".
Once the trial program for the AsepticSure™ hospital sterilization system is concluded, MZEI expects to out-source the manufacturing of the product and partner with large, well established companies that are already fully embedded in their sector of business as suppliers, such as medical device manufacturers or service companies.
Medizone possibly may partner with several such companies, perhaps covering different geographical markets such as North America, Asia, and Europe. The same may prove to be true for the outsourcing of additional manufacturing capacity. By developing relationships with multiple corporate partners, management believes that they will be able to better maintain control over their products and obtain more competitive returns.
Management Team
- Edwin G. Marshall - Chairman of the Board and Chief Executive Officer
- Michael E. Shannon, M.A.,M.Sc.,M.D. - Board Member & Director of Medical Affairs
- Richard Garret Solomon – Director and Executive Officer
- Daniel D. Hoyt – Board Member
- Steve M. Hanni - Chief Financial Officer
The Future
The company believes that Medizone's unique ozone generating technologies could play a vital role in addressing what public health officials and surgeons worldwide are beginning to recognize as "the silent epidemic", a reference to MRSA (methicillin-resistant staphylococcus aureus) infection.
Medizone's management believes that there is an opportunity to build on the company's experience with ozone technologies and its bio-oxidative qualities in pursuing this initiative. The company has shifted its near term efforts towards one of its founding tenets, namely that under the right conditions, ozone can be extremely effective at sterilizing virtually all biological fluids (blood, serum, and plasma and its fractionates) as well as all biologically contaminated equipment and spaces.
Medizone’s CEO Edwin Marshall added, “Following the impressive results recently announced for MRSA, we immediately began to assess the capability of AsepticSure™ using the same updated technology with the spore forming bacteria C. difficile, which is ubiquitous within hospitals and chronic care centers. Following those results we then worked with Bacillus subtilis, which represents the infamous and highly lethal terrorist agent, Anthrax. In both cases, these two pathogens remain very resistant to standard decontamination procedures and hence, seeing our technology virtually annihilate these two difficult spore formers has lead Medizone to a parallel track of development with its AsepticSure™ technology which we are convinced will open up the possibility for commercialization in both arenas."
Medizone believes that a field hardened variant of the AsepticSure™ hospital unit currently being readied for scale up testing will have wide bio defense applications internationally as it will be easily deployable in response to virtually any terrorist assault, extremely effective against a broad range of lethal pathogens, easy to manage and maintain and most importantly, it has the potential to save lives. Medizone International, Inc. is poised to become a significant player in the healthcare industry!
MP has been compensated five thousand dollars from Medizone International, Inc. In addition, MP was also compensated two hundred fifty thousand restricted shares of Medizone International, Inc. by the company.
For additional information relating to MP, please review our disclosure page through our disclaimer link.
Current Profile | Profiles | Resources | Subscribe | Contact Us | Disclaimer
Market Pulse Navigator All Rights Reserved.
© Copyright 2010
Current Profile
